Literature DB >> 27331286

Cardiac and Renovascular Complications in Type 2 Diabetes--Is There Hope?

Julie R Ingelfinger1, Clifford J Rosen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27331286     DOI： 10.1056/NEJMe1607413

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  11 in total

Review 1.  Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents.

Authors:  David R Saxon; Neda Rasouli; Robert H Eckel
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

2.  Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials.

Authors:  Sanjay Basu; Jeremy B Sussman; Seth A Berkowitz; Rodney A Hayward; John S Yudkin
Journal:  Lancet Diabetes Endocrinol       Date:  2017-08-10       Impact factor: 32.069

3.  Trends in Diabetes Treatment and Monitoring among Medicare Beneficiaries.

Authors:  Bruce E Landon; Alan M Zaslavsky; Jeffrey Souza; John Z Ayanian
Journal:  J Gen Intern Med       Date:  2018-02-09       Impact factor: 5.128

Review 4.  Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises Unmet.

Authors:  James H Flory; Jenny K Ukena; James S Floyd
Journal:  Curr Atheroscler Rep       Date:  2016-12       Impact factor: 5.113

5.  Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial.

Authors:  Adeera Levin; Vlado Perkovic; David C Wheeler; Stefan Hantel; Jyothis T George; Maximilian von Eynatten; Audrey Koitka-Weber; Christoph Wanner
Journal:  Clin J Am Soc Nephrol       Date:  2020-09-29       Impact factor: 8.237

Review 6.  Bringing patient centricity to diabetes medication access in Canada.

Authors:  Judith L Glennie; Katharina Kovacs Burns; Paul Oh
Journal:  Clinicoecon Outcomes Res       Date:  2016-10-17

7.  Phosphodiesterase-5 inhibition preserves renal hemodynamics and function in mice with diabetic kidney disease by modulating miR-22 and BMP7.

Authors:  Riccardo Pofi; Daniela Fiore; Rita De Gaetano; Giuseppe Panio; Daniele Gianfrilli; Carlotta Pozza; Federica Barbagallo; Yang Kevin Xiang; Konstantinos Giannakakis; Susanna Morano; Andrea Lenzi; Fabio Naro; Andrea M Isidori; Mary Anna Venneri
Journal:  Sci Rep       Date:  2017-03-15       Impact factor: 4.379

Review 8.  Precision medicine in diabetes prevention, classification and management.

Authors:  Fangying Xie; Juliana Cn Chan; Ronald Cw Ma
Journal:  J Diabetes Investig       Date:  2018-04-25       Impact factor: 4.232

9.  Efficacy and Effectiveness Too Trials: Clinical Trial Designs to Generate Evidence on Efficacy and on Effectiveness in Wide Practice.

Authors:  Harry P Selker; Hans-Georg Eichler; Norman L Stockbridge; Newell E McElwee; Willard H Dere; Theodora Cohen; John K Erban; Vicki L Seyfert-Margolis; Peter K Honig; Kenneth I Kaitin; Kenneth A Oye; Ralph B D'Agostino
Journal:  Clin Pharmacol Ther       Date:  2019-02-12       Impact factor: 6.875

10.  Use of diabetes medications in traditional Medicare and Medicare Advantage.

Authors:  Bruce E Landon; Alan M Zaslavsky; Jeffrey Souza; John Z Ayanian
Journal:  Am J Manag Care       Date:  2021-03-01       Impact factor: 2.229
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.